Veterinary News and Research

RSS

SANUWAVE third quarter revenues increase to $278,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and nine months ended September 30, 2010 and provided a business update.

12 Nov 2010

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

In a major breakthrough that comes after decades of research and nearly half a billion treatments in humans, scientists have finally unlocked how a key anti-parasitic drug kills the worms brought on by the filarial diseases river blindness and elephantitis.

11 Nov 2010

FDA awards 84 grants worth $18.5 million to boost food and feed safety initiatives

The U.S. Food and Drug Administration awarded 84 grants worth $18.5 million in fiscal year 2010 to help state and local regulatory agencies defend against and respond quickly to threats to the food supply and to outbreaks of foodborne diseases.

29 Oct 2010

Henry Schein third quarter net sales increases 14.1% to $1.9 billion

Henry Schein, Inc. the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended September 25, 2010.

29 Oct 2010

Parasitic disease inflicts damage to women's reproductive organs: Research

Faculty of Life Sciences at the University of Copenhagen shows that the parasitic disease, commonly known as snail fever, or schistosomiasis, almost eats its way into women's reproductive organs. Today researchers from all over the world are gathering in Copenhagen to find out what can be done to halt the disease which is affecting millions of women in Africa.

29 Oct 2010

Researchers investigate reverse zoonosis in marine invertebrate

The spread of lethal diseases from animals to humans has long been an issue of great concern to public health officials. But what about diseases that spread in the other direction, from humans to wildlife. A multidisciplinary team of researchers at the University of Georgia has just been awarded a five-year $2 million Ecology of Infectious Diseases grant from the National Science Foundation and National Institutes of Health to study the first known case of such a "reverse zoonosis" that involves the transmission of a human pathogen to a marine invertebrate, elkhorn coral.

21 Oct 2010

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.

18 Oct 2010

Researchers unveil clues to combat enteritis in humans

The bacterium Campylobacter jejuni is a major cause of food poisoning in humans. It is normally transmitted from contaminted chicken meat, as it is frequently found in the intestines of chickens, where it apparently does not result in any symptoms. Researchers at the University of Veterinary Medicine, Vienna have now solved the puzzle, showing that Campylobacter can survive ambient oxygen levels thanks to the presence of other bacteria, species of Pseudomonas.

7 Oct 2010

Mylan subsidiary receives FDA approval for Fludarabine Phosphate Injection ANDA

Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).

4 Oct 2010

Researchers examine new genes to control mosquito-borne diseases

An Iowa State University researcher searched for new genes that are turned on during infection in a type of mosquito that is not only a pest, but transmits disease-causing pathogens.

4 Oct 2010

Critical piece of puzzle in treatment of Spinal Muscular Atrophy

University of Missouri researchers believe they have found a critical piece of the puzzle for the treatment of Spinal Muscular Atrophy (SMA) - the leading genetic cause of infantile death in the world. Nearly one in 6,000 births has SMA, and it is estimated that nearly one in 30 to 40 people have the trait that leads to SMA.

29 Sep 2010

LSU receives NIH grant to strengthen biomedical research infrastructure

LSU has received a $15 million grant from the National Institutes of Health, or NIH, IDeA Networks of Biomedical Research Excellence, or INBRE, program. The grant is centered in the School of Veterinary Medicine, or SVM, and the Department of Biological Science in the LSU College of Science. The purpose of this five-year grant is to strengthen the biomedical research infrastructure and work force within Louisiana.

28 Sep 2010

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI).

24 Sep 2010

Researchers renew call for governmental agencies to identify BPA products

Researchers have discovered that women, female monkeys and female mice have major similarities when it comes to how bisphenol A (BPA) is metabolized, and they have renewed their call for governmental regulation when it comes to the estrogen-like chemical found in many everyday products.

21 Sep 2010

BioNeutral third quarter revenue increases to $15,500

BioNeutral Group Inc., a specialty chemical technology-based life science company, today announced financial results for the third quarter and nine-month period ended July 31, 2010.

21 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

Center for One Health Illinois to receive additional $500,000 grant from USDA

The Center for One Health Illinois, established at the University of Illinois last year with a $250,000 grant from the U.S. Department of Agriculture, will receive another $500,000 in grants over several years from the USDA to pursue its mission of fostering collaborations and the free flow of information among those in the fields of medicine, public health, the environment and agriculture.

17 Sep 2010

Researchers identify interferons may inhibit IL-1b protein production

Among the first is the production of cell factors such as interferons and IL-1beta. Interferons have several functions, including activating a series of intracellular signals such as Tyk2 (Tyrosine kinase 2), while IL-1beta is important for the induction of inflammation, which helps directly to protect the body against attack.

16 Sep 2010

New computerized catheter makes surgical treatment of atrial fibrillation faster, cheaper and more effective

Atrial fibrillation is a heart disorder that affects more than two million Americans, and is considered a key contributor to blood clots and stroke. Now researchers from North Carolina State University are developing a new computerized catheter that could make the surgical treatment of atrial fibrillation faster, cheaper and more effective - while significantly decreasing radiation exposure related to the treatment.

16 Sep 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010